Results 131 to 140 of about 50,208 (253)

Efficacy and Safety of Intra‐Articular Therapies for Temporomandibular Disorders: A Systematic Review and Meta‐Analysis

open access: yesOral Diseases, EarlyView.
ABSTRACT Objective This systematic review and meta‐analysis aimed to evaluate the most effective minimally invasive intra‐articular procedure for reducing pain and improving maximum mouth opening (MMO) in individuals diagnosed with painful articular TMD, specifically TMJ osteoarthritis and/or internal derangement.
Mateus Gaya dos Santos   +5 more
wiley   +1 more source

RENAL AMYLOIDOSIS IN RHEUMATIC DISEASES

open access: yesTurkish Journal of Nephrology, 2019
In this study, cases with secondary amyloidosis due to rheumatic diseases were investigated retrospectively. Sixteen female, 14 male (mean age, 34±15 years) total 30 cases were included into the study. The number of cases with renal amyloidosis secondary
Yüksel KARAKOÇ   +6 more
doaj  

Juvenile Rheumatoid Arthritis [PDF]

open access: yes, 1982
Juvenile rheumatoid arthritis (JRA) (JA) has been the diagnostic label applied to any child whose arthritis is of unknown origin, begins under age 16, and persists for a minimum of 6 weeks.1,2 Arthritis is defined as swelling or both pain and limitation of motion in at least one joint.
openaire   +1 more source

Myocellular adaptations to short‐term weighted wheel‐running exercise are largely conserved during C26‐tumour induction in male and female mice

open access: yesExperimental Physiology, EarlyView.
Abstract This study investigated whether performing a translatable murine model of concurrent training after tumour induction affects adaptations in juvenile male and female tumour‐bearing mice. Male and female Balb/c mice were injected bilaterally with colon‐26 adenocarcinoma (C26) cells or PBS at 8 weeks of age.
Stavroula Tsitkanou   +10 more
wiley   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1514-1521, June 2026.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld   +9 more
wiley   +1 more source

Molecular Regulation of Bone Turnover in Juvenile Idiopathic Arthritis: Animal Models, Cellular Features and TNFα

open access: yesFrontiers in Bioscience-Landmark
We review the abnormal bone turnover that is the basis of idiopathic inflammatory or rheumatoid arthritis and bone loss, with emphasis on Tumor Necrosis Factor-alpha (TNFα)-related mechanisms.
Harry C Blair   +8 more
doaj   +1 more source

Is juvenile rheumatoid arthritis/juvenile idiopathic arthritis different from rheumatoid arthritis?

open access: yes, 2002
CHAPTER SUMMARY: The chronic arthropathies of childhood share clinical and pathological features with rheumatoid arthritis (RA) in adults. Both are autoimmune diseases characterized by a destructive arthropathy. Both are likely to be complex genetic traits, with autoantibodies and with a type-1-T-helper-cell cytokine profile in disease tissues.
Prahalad, Sampath, Glass, David N
openaire   +1 more source

Comorbidities and Treatment Patterns in People With Myasthenia Gravis in Denmark, Finland and Sweden: A Population‐Based Observational Study

open access: yesMuscle &Nerve, Volume 73, Issue 6, Page 1044-1057, June 2026.
ABSTRACT Introduction/Aims Comorbidities are frequent in myasthenia gravis (MG) and may affect treatment choices. Conversely, MG treatments may impact the risk of comorbidity. Our objective was to examine comorbidity and MG treatment patterns in nationwide MG cohorts in Denmark, Finland, and Sweden. Methods We included individuals with ≥ 2 MG diagnoses
Sari Atula   +11 more
wiley   +1 more source

Age‐Dependent Differences in Canakinumab Safety: A Comprehensive Pharmacovigilance Analysis Using the FAERS Database

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT While the efficacy of canakinumab, an anti‐interleukin‐1β monoclonal antibody, is well‐established, its safety profile, particularly across different age groups, remains inadequately explored. Using the FDA Adverse Event Reporting System (FAERS) database, this study evaluated postmarketing safety by analyzing adverse event (AE) reports from ...
Youyang Wang   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy